Urgent Need for COVID-19 Vaccine Development

Overview of COVID-19

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the urgent necessity for a safe and effective vaccine. This virus leads to coronavirus disease 2019 (COVID-19), affecting respiratory epithelial cells and resulting in symptoms that range from mild, such as fever and dry cough, to severe pneumonia.

The Importance of Vaccines

Vaccines that generate protective and long-lasting immune responses are considered the most effective and economical means of controlling outbreaks. Generally, the side effects associated with vaccinations are minimal, often limited to localized redness and swelling, along with flu-like symptoms.

Current Vaccine Trials

Worldwide, clinical trials are underway to assess the safety, efficacy, tolerability, and immunogenicity of various COVID-19 vaccine candidates. The World Health Organization indicates that at least 23 candidates are currently being tested in humans.

Targeting the Spike Protein

A crucial component of the coronavirus envelope is the surface spike protein, which serves as a primary target for vaccine development aimed at preventing COVID-19 infection.

Leading COVID-19 Vaccine Candidates

AZD1222

Developed by the University of Oxford in collaboration with AstraZeneca, AZD1222 is a chimpanzee adenovirus-vectored vaccine. This type of non-replicating viral vector acts as a live attenuated vaccine, designed to express coronavirus proteins upon immunization.

In Phase 1-2 trials involving 1077 volunteers, neutralizing antibodies against COVID-19 were detected in all participants 28 days post-vaccination. Most side effects, such as pain at the injection site, headaches, and fever, were moderately severe, indicating a good safety profile.

Currently, AZD1222 is in Phase 3 trials, where healthy adults aged 18 to 55 will receive either the investigational vaccine or a meningitis placebo vaccine. Participants will be monitored for 12 months, with the study expected to conclude in August 2021.

mRNA-1273

The mRNA-1273 vaccine is the first COVID-19 vaccine to enter clinical trials in the United States, developed by the National Institute of Allergy and Infectious Diseases (NIAID) in partnership with Moderna. This RNA vaccine utilizes lipid nanoparticles to deliver messenger RNA (mRNA) that prompts host cells to produce the spike protein, generating an antibody response.

Initial trials involving 45 healthy adults demonstrated that mRNA-1273 effectively induced neutralizing antibodies and T-cell responses. While generally well-tolerated, some participants reported fatigue, headaches, and muscle pain. The 100µg dose showed a favorable balance of high antibody responses and tolerability.

mRNA-1273 has advanced to Phase 3 trials. According to Dr. Anthony Fauci, Director of NIAID, early results suggest the vaccine is safe and immunogenic, paving the way for further testing to ascertain its efficacy in preventing COVID-19.

BNT162 mRNA

Developed by BioNTech and Pfizer, the BNT162 vaccine candidates represent a new class of nucleic acid vaccines that can be rapidly produced without containing live virus. Currently, these candidates are in Phase 2-3 trials in the United States and Germany.

The BNT162 series consists of multiple experimental vaccines, including BNT162b1 and BNT162b2, which utilize modified mRNA within lipid nanoparticles. Clinical trials for BNT162b1 have shown it can induce immunity and prevent COVID-19 infection, with side effects being dose-dependent.

BNT162b2 is now undergoing a Phase 2-3 trial involving 30,000 participants aged 18 to 85 at 120 global sites. In August 2020, Pfizer Canada and BioNTech announced plans to distribute the BNT162 vaccines in Canada pending successful clinical outcomes and regulatory approval.

Conclusion

Further research is essential to fully evaluate the effectiveness of these vaccine candidates against COVID-19. Professor Adrian Hill, Director of Oxford’s Jenner Institute, emphasized the urgency in vaccine development, stating, “People are working day and night and we’re not going to stop until we get an answer.”

References

Folegatti, P.M., et al. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. Retrieved from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext

Jackson, L.A., et al. (2020). An mRNA vaccine against SARS-CoV-2 – preliminary report. New England Journal of Medicine. Retrieved from: https://www.nejm.org/doi/10.1056/NEJMoa2022483

COVID-19 vaccine candidates show promising early results, but finish line still far ahead (2020). ABC News. Retrieved from: https://abcnews.go.com/Health/covid-19-vaccine-candidates-show-promising-early-results/story?id=71878984

Phase 3 clinical trial of investigational vaccine for COVID-19 begins (2020). NIH. Retrieved from: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins

Poland, G.A., Ovsyannikova, I.G. and Crooke, S.N. (2020). SARS-CoV-2 vaccine development: current status. In Mayo Clinic Proceedings. Elsevier.

A phase III study to investigate a vaccine against COVID-19 (2020). ISRCTN. Retrieved from: http://www.isrctn.com/ISRCTN89951424

Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy adults (2020). NIH. Retrieved from: https://www.clinicaltrials.gov/ct2/show/NCT04368728

Illi, B. (2020) The long and winding road to Covid-19 treatments and vaccines, part 2: from cardiovascular disease treatment to developing vaccines. Institute of Molecular Biology and Pathology.

Zhang, J., Xie, B. and Hashimoto, K. (2020). Current status of potential therapeutic candidates for the COVID-19 crisis. Brain, Behavior, and Immunity, 87, pp.59-73.

BNT162 SARS-CoV-2 vaccine (2020). Precision Vaccinations. Retrieved from: https://www.precisionvaccinations.com/vaccines/bnt162-sars-cov-2-vaccine